GeoVax to Announce Q3 2025 Financial Results and Business Update

GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced it will report financial results for the quarter ended September 30, 2025, after market close on November 13, 2025. The company's management will host a conference call and audio webcast at 4:30 p.m. ET to review results and provide a comprehensive business update, offering insights into the company's financial health and strategic direction.

The live conference call can be accessed through advance registration at https://edge.media-server.com/mmc/p/u86rmdmb/. Alternatively, the live audio webcast will be available via the Events & Presentations section of the company's Investor Relations website at https://www.geovax.com/investors. Telephone participants should register using the provided link to receive dial-in information, a unique passcode, and access instructions. While registration is not mandatory, participants are advised to join ten minutes before the scheduled start time to ensure proper connection.

GeoVax's lead clinical program includes GEO-CM04S1, a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients, including those with hematologic cancers and other populations where current authorized COVID-19 vaccines have shown limitations. Additionally, it's being studied as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.

In the oncology sector, GeoVax is advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox, and based on recent EMA regulatory guidance, anticipates progressing directly to Phase 3 clinical evaluation, bypassing Phase 1 and Phase 2 trials. This regulatory pathway could significantly accelerate the development timeline for this important vaccine candidate.

The company maintains a strong intellectual property portfolio supporting its technologies and product candidates, holding worldwide rights for its innovations. An archive of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain accessible for at least 90 days, providing ongoing access to the financial results and business updates for investors and stakeholders who cannot attend the live presentation.